Basal Cell Carcinomas
8
2
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Transcriptomic Analysis and Optical Coherence Tomography Combined for Patients With Basal Cell Carcinoma
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Ivonescimab in the Treatment of Multiple Advanced Tumors
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
Development of a Nanosecond Pulsed Electric Field System to Treat Skin Cancer
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight